On-Demand Videos

New Evidence from 2025 SABCS and Beyond Reinforcing: The Breast Cancer Index Test remains the leading test for extended endocrine therapy decision-making: Exclusive Guideline Recognition. Extensively Validated. Proven Clinical Impact. Endocrine therapy adherence remains a challenge, with a significant percentage of women discontinuing treatment prior to the 5-year mark. New data supporting expanded applications of the Breast Cancer index Test will support earlier personalized decisions to help women avoid unnecessary side effect or gain commitment to their treatment plan from the start (coming soon).* *Not currently available to order The features and results of the Breast Cancer Index Test, to the extent they differ from the information found on the breastcancerindex.com website, including, but not limited to, the features concerning adjuvant endocrine therapy and ovarian function suppression: (i) are not currently available for clinical use; (ii) will be made available only after all required internal validations and regulatory requirements have been met; and (iii) is being provided herein for informational purposes only, and shall not be deemed to be an offer of availability.

An expert exchange with Dr. Rena Callahan* (UCLA) and Dr. Vijay Paryani* (Duke Health) focused on: Navigating evolving genomic testing options to help inform treatment recommendations Integrating recent-meta-analysis results into individualized patient care Translating data into personalized clinical decisions through patient case reviews *Speakers listed are consultants of Biotheranostics, Inc. Statements reflect the speakers’ own personal views and interpretations.

Linda Moors, PA-C* partnered with her patient Cheryl to make important decisions regarding her breast cancer treatment. When it came to making a decision about extended endocrine therapy, they both knew the Breast Cancer Index® Test would help give Cheryl the personalized answers she wanted. *Linda Moors, PA-C is a consultant of Biotheranostics, Inc. Statements reflect the speakers’ own personal views and interpretations.

A case-based program on the management of patients with early-stage, HR+ breast cancer. Rena Callahan, MD* and Katherine Cohen, NP* from University of California, Los Angeles review recently published data and guidelines for extended endocrine therapy, discuss collaboration between Medical Oncologists and Advanced Practice Providers in the management of breast cancer survivors and discuss real-world cases with a focus on avoiding over- and under- treatment. *Speakers listed are consultants of Biotheranostics, Inc. Statements reflect the speakers' own personal views and interpretations.

Watch Drs. Rena Callahan*, UCLA Health, and VK Gadi*, University of Illinois Cancer Center, discuss evolving trends in early-stage, HR+ breast cancer diagnostics. Listen to them present the data on the Breast Cancer Index® Test and discuss utilization of the test in clinical case studies. *Speakers listed are consultants for Biotheranostics, Inc. Statements reflect the speakers’ own personal views and interpretations.